According to Stock Talk (@stocktalkweekly), Raymond James has reiterated its Strong Buy rating on Trevi Therapeutics ($TRVI) with a $29 price target, following the company's presentation of new clinical data at a KOL panel during the ATS event. This renewed analyst confidence, backed by tangible data releases, indicates heightened institutional interest and potential for significant price movement in $TRVI. For crypto traders, strong moves in biotech equities like TRVI can impact sentiment and capital flow in related crypto healthcare tokens, especially those tied to medical technology and bio-data blockchain projects. Source: Stock Talk (@stocktalkweekly), May 20, 2025.